GlobeNewswire

Disruptive Semiconductor Technology Leader Luxcore Signs Multi-year Colocation Deal with INAP

Dela

Luxcore selects INAP to support their ground breaking second generation LambdaRouterTM --- the first full wavelength optical router.

INAP chosen for its global presence in strategic markets, carrier neutrality and signature Performance IPTM service.

ATLANTA, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Internap Corporation (NASDAQ:INAP), ("INAP" or the "Company"), a provider of high-performance internet infrastructure including colocation, cloud and network services, and Luxcore, pioneers of a revolutionary all-optical wavelength routing platform, today announced a multi-year agreement for colocation services in seven global locations. 

Luxcore, creator of the LambdaRouterTM - the world's first all-optical, wavelength switching, routing and transport system, selected INAP as its strategic partner to access the company's global coverage and connectivity to Tier 1 providers, utilizing INAP's access to dark fiber at all its locations.  To demonstrate its disruptive technology during its initial rollout, Luxcore selected seven INAP data centers in the following major markets: Atlanta, Dallas, Silicon Valley (Santa Clara), New York & New Jersey Metro Area, Northern Virginia & D.C. Metro Area, Singapore and Amsterdam.  

"Luxcore is poised to lead a significant shift in the underlying technology of the internet and we are excited to be their partner on that journey," said Corey Needles, INAP COLO's SVP and General Manager. "Given our global reach and network connectivity utilizing multiple carrier networks and our own fiber, we are uniquely positioned to help Luxcore succeed."

Luxcore is strategically partnering with INAP in a flagship venture to deliver the industry's first all-optical wavelength switching, routing and transport capabilities of the second generation LambdaRouterTM.  When combined with INAP's global reach, unprecedented Tier 1 interconnectivity and dark fiber, Luxcore will introduce the "Optical Internet" providing significant new revenue opportunities for both INAP and Luxcore.

"When we introduced our first LambdaRouterTM in Spring of 2001, it was the world's first and only multi-terabit wavelength switching, routing and transport system based on proprietary optical semiconductor technology. The global telecom market subsequently collapsed and many said we were way ahead of our time. 15 years ago, there was no demand for such robust optical capacity. Fast forward to today's mobile, social and device-driven data economy and the need for ultra-high speed bandwidth is an absolute necessity. Global internet traffic has grown exponentially measured in zettabytes, and the underlying backbone infrastructure has hit a wall. Partnering with INAP allows Luxcore to fulfill its original corporate vision - to build the new 'Optical Internet,'" said Gerald Ramdeen, Luxcore Chairman and CEO.

With over 1 million square feet in 21 metropolitan markets and 89 POPs, INAP's collocation and network services offers the proximity and connectivity needed for INAP customers to be successful in the global marketplace. 

About INAP

Internap Corporation (NASDAQ: INAP) is a leading provider of internet infrastructure through both Colocation Business and Enterprise Services (including colocation, network connectivity, IP, bandwidth and managed hosting) and Cloud Services (including enterprise-grade AgileCLOUD, bare-metal servers and SMB iWeb platforms). INAP operates in Tier 3-type data centers in 21 metropolitan markets, primarily in North America, with 50 data centers and 89 POPs around the world. INAP operates a premium business model that provides high-power density colocation, low-latency bandwidth, and public and private cloud platforms in an expanding internet infrastructure industry. For more information, visit www.INAP.com

About Luxcore

2001, Luxcore introduced the LambdaRouterTM - the world's first fully-integrated, all-optical switching, routing and transport system built upon proprietary semiconductor technology having origins from the Stanford University Center for Novel Optoelectronic Materials (CNOM), demonstrating 2.5Gbs and 10Gbs single port speeds at the lowest cost per bit. Luxcore Networks, Luxcore Optronics, Jedai Networks, (formerly Jedai Broadband Networks) - now Luxcore, Inc. has since leveraged in excess of $100MM in venture funding from prominent VC and private equity firms to develop the second generation of our award-winning LambdaRouterTM and the LambdaExchangeTM - introducing 100Gbs single port speeds at the lowest cost per bit.  For more information, visit www.luxcore.com.

NAP Media Contacts                           

Richard Ramlall, VP IR & PR  
(404) 302-9982                           

Clay Boothby                             
(202) 595-4923          

Luxcore Media Contacts

Tamer Yacoub, VP Corporate Alliances
(212) 618-1724 

Dino Ianniello                   
SilverMoss
(770) 573-1733




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Internap Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum